Patent ID: 9393292
Filing Date: 2016-07-19
CPC Classification: A61K,A61P,C07K,C12N,C12Y

Claim Text:
1. A method of controlling the survival of therapeutic cells in a human patient, comprising administering a multimeric ligand to a human patient to whom therapeutic cells have been administered, wherein: the therapeutic cells have been transfected or transduced with a nucleic acid comprising (i) a promoter region, and (ii) a polynucleotide that encodes a chimeric protein comprising a multimeric ligand binding region and a caspase 9 polypeptide; the promoter region is operatively linked to the polynucleotide; the multimeric ligand binds to the multimeric ligand binding region; the multimeric ligand binding region comprises a modified FKBP12 polypeptide; the modified FKBP12 polypeptide binds with higher affinity to the multimeric ligand than the wild type FKBP12 polypeptide; the modified FKBP12 polypeptide comprises an amino acid substation at position 36; the number of therapeutic cells that express the caspase 9 polypeptide is reduced at least 90% within 24 hours following administration of the multimeric ligand.